{"text_format":"2","workbook":"xlsx","n_sheets":3,"sheets":["Sheet1","Sheet2","Sheet3"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":0,"defined_names":0,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Sheet1","index":0,"n_rows":14,"n_cols":3,"rows_kept":14,"cut":false,"hidden":false,"merged":[]}
["Number","Trials","Reasons to Exclude"]
[1,"Cacheux, C., et al. (2012) Effect of high versus low dose of tranexamic acid (TXA) on fibrinolysis during cardiac surgery. European journal of anaesthesiology. 29, 95 ","This was a conference abstract , and no specific data on Transfusion,blood loss and adverse events was reported. The result only reported no difference between groups."]
[2,"Coffey, A., et al. (1995). \"The use of tranexamic acid to reduce postoperative bleeding following cardiac surgery: A double-blind randomized trial.\" American Surgeon 61(7): 566-568.","Data on blood loss and transfusion requirement provided were in median(range), and we were unable to get the original data."]
[3,"Compton, F., et al. (2018). \"Intraoperative administration of antifbrinolytic drug tranexamic acid is not associated with decreased intraoperative blood loss during major cardiac surgery.\" American Journal Of Clinical Pathology 149: S177-S178.","This trial studied intraoperative blood loss only and did not provide any information concerning post operative blood loss, This trial also exluded patients \"who receive significant intraoperative transfusion\" without explaining the reason."]
[4,"Jamieson, W. R. E., et al. (1997). \"Beneficial effect of both tranexamic acid and aprotinin on blood loss reduction in reoperative valve replacement surgery.\" Circulation 96(9 SUPPL.): II96-II101.","This trial only provide the mean of blood loss without reporting SD and P valus, It also failed to report specific informatino on blood transfusion, and only reported no difference between groups. "]
[5,"Leelahanon, S., et al. (2002). \"Can Tranexamic Acid Improve Post Cardiopulmonary Bypass Hemostasis? A Double-Blind Prospective Randomized Placebo-Controlled Study.\" Thai journal of surgery 23(4): 138.\n","The result of this study wasn't found. We only identied an abstract of study protocol."]
[7,"https://clinicaltrials.gov/ct2/show/nct01600599","The research protocol met with our inclusion criteria, but no results have been reported so far."]
[8,"https://clinicaltrials.gov/ct2/show/study/NCT01519245","This result of this trial was published in the article named Dual-route tranexamic acid to reduce blood loss in coronary artery bypass graft surgery: a randomized controlled trial.This articel was excluded from analysis for reason listed below"]
[9,"Prokopchuk-Gauk, O., et al. (2016). \"Dual-route tranexamic acid to reduce blood loss in coronary artery bypass graft surgery: a randomized controlled trial.\" Canadian Journal of Anesthesia 63(9): 1110-1111.","Both experiment group with topical TXA application and control group received 30mg/kg of intravenous TXA application, and this diagreed with our inclusion criteria. "]
[10,"Yanartas, M., et al. (2015). \"The effects of tranexamic acid and 6% hydroxyethyl starch (HES) solution (130/0.4) on postoperative bleeding in coronary artery bypass graft (CABG) surgery.\" International Journal of Clinical and Experimental Medicine 8(4): 5959-5971.","Patients received 6% hydroxyethyl starch (HES) into Ringer lactate priming solution which may have adverse effects on hemostasis and affect the result."]
[11,"van Diepen, S., et al. (2017). \"Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery.\" Journal of thrombosis and thrombolysis 43(4): 446-453.","The population studied in this trial was from a RCT, but it was not ramdomed on whether patients receive TXA or not."]
[12,"Shi, J., et al. (2013) Effectiveness and safety of tranexamic acid in patients receiving on-pump coronary artery bypass grafting without clopidogrel and aspirin cessation. Zhonghua Wai Ke Za Zhi 51, 527-532 ","This study only reported part of the results from a trial conducted by the team, and more comprehensive and updated information was published in another article which we included into analysis."]
[13,"Prokopchuk-Gauk, O., et al. (2012) Topical application of tranexamic acid to reduce post-operative bleeding in coronary artery bypass surgery. Blood 120,  ","Data on blood loss were in median(range), and we were unable to get the original data."]
[14,"Ovrum, E., et al. (1993). \"Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations.\" Journal of Thoracic and Cardiovascular Surgery 105(1): 78‐83.","The process of randomization was not valid in this trial, quote \"two hundred patients undergoing elective coronary artery bypass operations were studied, one group of 100 patients given tranexamic acid (40 mg/kg) (group I) after bypass and one subsequent group of 100 patients (group II) serving as a control group.\""]

{"sheet":"Sheet2","index":1,"n_rows":0,"n_cols":0,"rows_kept":0,"cut":false,"hidden":false,"merged":[]}

{"sheet":"Sheet3","index":2,"n_rows":0,"n_cols":0,"rows_kept":0,"cut":false,"hidden":false,"merged":[]}